95
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study.

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Drug treatments for patients with high-risk myelodysplastic syndromes provide no survival advantage. In this trial, we aimed to assess the effect of azacitidine on overall survival compared with the three commonest conventional care regimens.

          Related collections

          Author and article information

          Journal
          Lancet Oncol
          The Lancet. Oncology
          Elsevier BV
          1474-5488
          1470-2045
          Mar 2009
          : 10
          : 3
          Affiliations
          [1 ] Hôpital Avicenne, Université Paris XIII, Bobigny, France.
          Article
          S1470-2045(09)70003-8 NIHMS428850
          10.1016/S1470-2045(09)70003-8
          4086808
          19230772
          9a2d0191-3d5c-47e4-82fd-bb415b65c0be
          History

          Comments

          Comment on this article